Trial Search Results

Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive iodine entering breast cancer cells, how long your cancer retains the agent as well as how much is taken up by other organs, particularly the thyroid gland.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Susan G. Komen Breast Cancer Foundation


Inclusion Criteria:- Only women diagnosed with breast cancer

   - 18 years of age or older

   - From whom informed consent can be obtained

   - Patient is able to provide a fluid (e.g. cyst fluid)

   - Patient with blood test that shows protein may allow iodide to accumulate in breast

   - Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours
   Exclusion Criteria:- Males

   - Children

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Marilyn Florero